MDGL - Company ID 0001157601
The table below shows MADRIGAL PHARMACEUTICALS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $311.34M | $287.27M | $212.80M | $137.25M | $62.17M | $14.64M |
| Cost of revenue | - | - | - | $4.51M | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
MADRIGAL PHARMACEUTICALS, INC. reported annual revenue of $958.40M for fiscal year 2025. That is up 432.1% from $180.13M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $147.00K (FY 2012) to $958.40M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $268.52M |
| $209.12M |
| $196.86M |
| $167.88M |
| $107.58M |
| $105.45M |
| Operating income | -$92.72M | -$113.97M | -$47.20M | -$79.31M | -$116.30M | -$162.54M |
| Income tax | - | - | - | - | - | - |
| Net income | -$94.39M | -$114.19M | -$42.28M | -$73.24M | -$106.96M | -$151.97M |
| EPS (diluted) | -$3.25 | -$4.01 | -$1.50 | -$2.61 | -$4.92 | -$7.10 |